Top Markets
Coin of the day
Antibe Therapeutics Inc. Antibe Therapeutics Inc.

Antibe Therapeutics Inc.

ATE
Pozycja w akcjach #32096
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Cena akcji
$0.21483059
Ostatnia synchronizacja: 2024-05-07
Kapitalizacja rynkowa
$11.13M
Zmiana (1 dzień)
0.34%
Zmiana (1 rok)
0.00%
Kraj
CA
Handel Antibe Therapeutics Inc. (ATE)

Kategoria

Wskaźnik P/B dla Antibe Therapeutics Inc. (ATE)
Wskaźnik P/B na dzień 2026 TTM: 0
Według najnowszych raportów finansowych i ceny akcji Antibe Therapeutics Inc., obecny wskaźnik P/B (TTM) wynosi 0. Na koniec 2026 wynosił 0.
Historia wskaźnika P/B dla Antibe Therapeutics Inc. od 2026 do 2026
Wskaźnik P/B na koniec każdego roku
Rok Wskaźnik P/B Zmień
Za mało danych dla podanych dat.
Wskaźnik P/B dla podobnych firm lub konkurentów
Firma Wskaźnik P/B Różnica wskaźnika P/B Kraj
3.7944 -
US
5.423 -
US
2.0146 -
IE
3.072 -
US
4.9725 -
US